• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    2/12/24 4:23:01 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email
    SC 13G/A 1 form_sc13ga-biote.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    __________________________________________
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     
     __________________________________________

    biote Corp.
    (Name of Issuer)
    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    090683103
    (CUSIP Number)
    December 31, 2023
    (Date of event which requires filing of this statement)
     
     __________________________________________

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
     
    ☒
    Rule 13d-1(b) 
     
     
    ☒
    Rule 13d-1(c) 
     
     
    ☐
    Rule 13d-1(d) 
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR Multi-Strategy Master Fund Limited
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR CCSA Master Fund Ltd
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR Partners LLP
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    PN, IA
     

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR Partners Limited
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Hong Kong
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO, IA
     

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR Partners LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    State of Delaware
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    OO, IA
     

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR Partners AG
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO, IA
     

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    LMR Partners (DIFC) Limited
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Arab Emirates
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO, IA
     

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    Ben Levine
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC
     

             
    CUSIP No. 090683103
     
    13G
     
     
     
                 
    1
     
    NAMES OF REPORTING PERSONS
     
    Stefan Renold
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐ (b) ☐
     
    3
     
    SEC USE ONLY
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
                 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
     
    0
     
    6
     
    SHARED VOTING POWER
     
    0
     
    7
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8
     
    SHARED DISPOSITIVE POWER
     
    0
                 
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC
     

    Item 1(a).
    NAME OF ISSUER:

    The name of the issuer is biote Corp. (the “Issuer”).
     
    Item 1(b).
    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

    The Issuer’s principal executive offices are located at 1875 W. Walnut Hill Ln #100, Irving, TX 75038.
     
    Item 2(a).
    NAME OF PERSON FILING:

    This statement is filed by:
     
     
    (i)
    LMR Multi-Strategy Master Fund Limited (“LMR Master Fund”), with respect to the shares of Class A Common Stock (as defined in Item 2(d)) issuable upon the exercise of warrants previously held by it;
     
     
    (ii)
    LMR CCSA Master Fund Ltd (“LMR CCSA Master Fund”), with respect to the shares of Class A Common Stock (as defined in Item 2(d)) issuable upon the exercise of warrants previously held by it;
     
     
    (iii)
    LMR Partners LLP, LMR Partners Limited, LMR Partners LLC, LMR Partners AG and LMR Partners (DIFC) Limited (collectively, the “LMR Investment Managers”), which serve as the investment managers to certain funds, including, without limitation, LMR Master Fund and LMR CCSA Master Fund, with respect to the shares of Class A Common Stock issuable upon the exercise of warrants previously held by LMR Master Fund and LMR CCSA Master Fund; and
     
     
    (iv)
    Ben Levine and Stefan Renold, who are ultimately in control of the investment and voting decisions of the LMR Investment Managers with respect to the securities previously held by LMR Master Fund and LMR CCSA Master Fund.

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
     
    Item 2(b).
    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

    The address of the principal business office of each of the Reporting Persons is c/o LMR Partners LLP, 9th Floor, Devonshire House, 1 Mayfair Place, London, W1J 8AJ, United Kingdom.

    Item 2(c).
    CITIZENSHIP:

    LMR Master Fund is a Cayman Islands exempted company. LMR CCSA Master Fund is a Cayman Islands exempted company. LMR Partners LLP is a United Kingdom limited liability partnership. LMR Partners Limited is a Hong Kong corporation. LMR Partners LLC is a Delaware limited liability company. LMR Partners AG is a Swiss corporation. LMR Partners (DIFC) Limited is a United Arab Emirates corporation. Ben Levine is a citizen of the United Kingdom. Stefan Renold is a citizen of Switzerland.
     
    Item 2(d).
    TITLE OF CLASS OF SECURITIES:

    Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”).
     
    Item 2(e).
    CUSIP NUMBER:

    090683103
     


    Item 3.
    IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
     
             
    (a)
     
    ☐
     
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).
         
    (b)
     
    ☐
     
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)
     
    ☐
     
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)
     
    ☐
     
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e)
     
    ☒
     
    An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).
         
    (f)
     
    ☐
     
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
         
    (g)
     
    ☒
     
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
         
    (h)
     
    ☐
     
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
         
    (i)
     
    ☐
     
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
         
    (j)
     
    ☒
     
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
    (k)
     
    ☐
     
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).
         
     
     
     
     
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: investment adviser.
     
    Item 4.
    OWNERSHIP.

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Each of LMR Master Fund and LMR CCSA Master Fund does not directly hold any warrants to purchase shares of Class A Common Stock.
     
    Item 5.
    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.
     
    Item 6.
    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Not applicable.
     
    Item 7.
    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not applicable.
     


    Item 8.
    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable.
     
    Item 9.
    NOTICE OF DISSOLUTION OF GROUP.

    Not applicable.

    Item 10.
    CERTIFICATION.

    Each of the LMR Investment Managers and Messrs. Levine and Renold hereby certifies as follows:

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Each of the LMR Investment Managers other than LMR Partners LLC hereby certifies as follows:

    By signing below, I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to an investment adviser is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Securities and Exchange Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

    Each of LMR Master Fund and LMR CCSA Master Fund hereby certifies as follows:

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 12, 2024
     
    LMR MULTI-STRATEGY MASTER FUND LIMITED
     
    By: LMR Partners LLP, its Investment Manager
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    LMR CCSA MASTER FUND LTD
     
    By: LMR Partners LLP, its Investment Manager
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    LMR PARTNERS LLP
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    LMR PARTNERS LIMITED
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    LMR PARTNERS LLC
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    LMR PARTNERS AG
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    LMR PARTNERS (DIFC) LIMITED
       
    By:
     
    /s/ Shane Cullinane
    Name:
     
    Shane Cullinane
    Title:
     
    Chief Operating Officer
     
    /s/ Ben Levine
    BEN LEVINE
     
    /s/ Stefan Renold
    STEFAN RENOLD

    Get the next $BTMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Announces Purchase of Shares by Directors and CEO

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of Biote's common stock, acquiring an aggregate of approximately 260,000 shares. Marc Beer, Biote Executive Chairman, said, "These share purchases underscore the collective confidence of Biote's Board members and CEO Bret Christensen in the Company's business strategy and long-term outlook. The board is very confident in Bret's ability to make decisive and material changes a

      3/18/25 5:30:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Biote to Purchase Asteria Health

      Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

      1/17/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Names Robert Peterson as Chief Financial Officer

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

      1/11/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on biote Corp.

      Craig Hallum initiated coverage of biote Corp. with a rating of Buy

      12/16/24 8:50:55 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities initiated coverage on biote Corp. with a new price target

      B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

      2/20/24 6:47:29 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on biote Corp.

      Jefferies initiated coverage of biote Corp. with a rating of Buy

      2/1/24 6:18:15 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Financials

    Live finance-specific insights

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Fourth Quarter and Full Year 2024 Financial Results

      Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

      3/12/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biote Corp.

      SC 13G/A - biote Corp. (0001819253) (Subject)

      11/12/24 4:15:18 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 5:17:02 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 2:11:05 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Biote Corp.

      10-Q - biote Corp. (0001819253) (Filer)

      5/9/25 4:21:16 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - biote Corp. (0001819253) (Filer)

      5/7/25 4:06:53 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFR14A filed by Biote Corp.

      DEFR14A - biote Corp. (0001819253) (Filer)

      5/5/25 4:51:15 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care